Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ReShape Lifesciences, Inc. - Common Stock (NQ:RSLS)

0.3750 -0.0119 (-3.08%)
Streaming Delayed Price Updated: 10:07 AM EDT, Mar 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ReShape Lifesciences, Inc. - Common Stock

< Previous 1 2 3 Next >
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FNA, AVTE, RSLS on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS
From Kahn Swick & Foti, LLC
Via Business Wire
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
Vagal Neuromodulation Provides Route to Treat Type 2 Diabetes and Hypoglycemia 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX
Liaison Medical is Among the Largest Surgical Device Distributors in Canada 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology
Vagal Neuromodulation Provides Path to Treat Type 2 Diabetes and Hypoglycemia 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
Transactions Continue to Progress and Remain on Track 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
Conference Call to be Held at 4:30 pm ET on Thursday, November 14, 2024 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX
FLEX Technology Designed to Improve the Patient Experience 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California’s Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape’s Proprietary Diabetes
Approximately $241,000 Grant Will Be Utilized to Conduct Minimally Invasive Laparoscopic Surgical Electrode Implantation Techniques and Long Duration Safety and Blood Glucose Modulation Experiments for... 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences Announces 1-for-58 Reverse Stock Split
Effective as of Commencement of Trading on September 23, 2024 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Reports Second Quarter Ended June 30, 2024 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
Conference Call to be Held at 4:30 pm ET on Thursday, August 15, 2024 
From ReShape Lifesciences Inc
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHUY, RSLS on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS
From Kahn Swick & Foti, LLC
Via Business Wire
RSLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of ReShape Lifesciences Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
Conference Call to be Held at 4:30 pm ET on Wednesday, May 15, 2024 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System
Patent Significantly Strengthens Intellectual Property Portfolio 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX
First Time Introduction of Lap-Band® 2.0 FLEX to the Next Generation of Surgeons 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update
Conference Call to be Held at 5:00 pm ET on Wednesday, November 8, 2023 
From ReShape Lifesciences Inc
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.